Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age14+
SponsorChinese PLA General Hospital
About this trial
Patients with newly diagnosed, pathologically confirmed NK/T-cell lymphoma of stage III-IV treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.
Eligibility criteria
Qualifiers
Age≥14 years, male or female;
Pathologically confirmed newly diagnosed NK/T cell lymphoma according to WHO classification criteria 2016;
At least one measurable lesion, defined as bidimensionally measurable, intranodal lesion > 1.5 cm in short axis and extranodal lesion > 1.0 cm in short axis;
ECOG score 0~2;
Disqualifiers
Prior allogeneic HCT (allo-HCT)
Active autoimmune disease
Primary central nervous system lymphoma;
Patients with infection which requiring treatment. Could be re-enrollment after infection control;
Trial design
Treatments tested in this trial
- XPO1 inhibitor
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov